TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32485993
Drug: 1290 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1290 mg green oat extract
Study: 32485993
Drug: 1290 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1290 mg green oat extract (after four weeks)
Study: 32485993
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1290 mg green oat extract
Study: 32485993
Drug: Four weeks
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weeks of supplementation with 430 mg and 1290 mg green oat extract
Study: 33552234
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU subcutaneous growth hormone (GH) administered every other day for 3 months
Study: 33552234
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU subcutaneous growth hormone (GH)
Study: 35763704
Drug: Atezolizumab with
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and pertuzumab-trastuzumab (PH)
Study: 35763704
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and pertuzumab-trastuzumab (PH)
Study: 35763704
Drug: Atezolizumab with
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and PH
Study: 35763704
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and PH
Study: 34480632
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline administration
Study: 33872801
Drug: Responsive preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responsive preventive intervention including point of care testing for early infant HIV diagnosis and maternal viral load, and infant single-drug Pre-Exposure Prophylaxis (lamivudine) if mothers are virally unsuppressed.
Study: 36241476
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (MG+)
Study: 36241476
Drug: No magnesium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No magnesium supplementation (MG−)
Study: 34684517
Drug: MNPs containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNPs containing 10 mg of zinc
Study: 34684517
Drug: Dispersible tablet
Normalized name: Aspirin 75 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablet containing 10 mg zinc
Study: 34812472
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional physical therapy)
Study: 36098519
Drug: Ensitrelvir 125
Normalized name: ensitrelvir
DrugBank: Ensitrelvir (DB18834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensitrelvir 125 mg
Study: 36098519
Drug: Ensitrelvir 250
Normalized name: ensitrelvir
DrugBank: Ensitrelvir (DB18834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensitrelvir 250 mg
Study: 32710741
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (>2.1 g · kg LBM‐1 · d‐1)
Study: 32710741
Drug: Recommended protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended protein intake (1.1 g · kg LBM‐1 · d‐1)
Study: 35473809
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) prophylaxis
Study: 36121686
Drug: Cash transfer
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash transfer along with combination HIV prevention (CHP) interventions
Study: 34044875
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg neflamapimod, orally twice daily for 24 weeks
Study: 32085394
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor (dapagliflozin: up to 10 mg/day)
Study: 35691282
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg per day of N-Acetyl-Cysteine (NAC) for 12 weeks
Study: 35691282
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of Selenium (Se) per day for 12 weeks
Study: 35691282
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of Selenium (Se) and 600 μg of NAC per day for 12 weeks
Study: 32050222
Drug: Intracameral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral moxifloxacin 500 μg
Study: 32050222
Drug: Intracameral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral moxifloxacin 250 μg
Study: 34162484
Drug: Ferric derisomaltose
Normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric derisomaltose (FDI) 1,000 mg
Study: 34162484
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (IS) 200 mg (up to 5 doses, recommended cumulative dose 1,000 mg)
Study: 32102472
Drug: Karaoke training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karaoke training (once a week for two hours, with an hour of homework assigned weekly)
Study: 35933083
Drug: δ‐tocotrienol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: δ‐tocotrienol 300 mg twice daily for 48 weeks
Study: 35933083
Drug: α‐tocopherol 268
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐tocopherol 268 mg twice daily for 48 weeks
Study: 32029499
Drug: 2.8 mg
Normalized name: pectin 2.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 mg folic acid with 60 mg iron weekly for 16 weeks
Study: 32029499
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg folic acid with 60 mg iron weekly for 16 weeks
Study: 32029499
Drug: 0.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg (placebo) folic acid with 60 mg iron weekly for 16 weeks
Study: 32074418
Drug: Nemolizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab (0.5 mg/kg, subcutaneously at baseline, week 4, and week 8)
Study: 34582636
Drug: Unani formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unani formulation
Study: 33649972
Drug: 2-week spa
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week spa therapy with low-dose radon therapy
Study: 33649972
Drug: 2-week spa
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week spa therapy without radon therapy
Study: 33649972
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (with and without radon therapy)
Study: 36280642
Drug: Crofelemer 125
Normalized name: crofelemer 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crofelemer 125 mg orally twice daily during chemotherapy cycles 1 and 2
Study: 36280642
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no scheduled prophylactic medication)
Study: 32934365
Drug: Novel anticancer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel anticancer agents and combination therapies
Study: 32934365
Drug: Single-agent or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent or combination therapies
Study: 32934365
Drug: Multiple agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple agents in a head-to-head comparison
Study: 32037096
Drug: Sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual (SL) administration of edaravone 60 mg
Study: 32037096
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion of edaravone 60 mg
Study: 33058438
Drug: Phenytoin (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (4-6 mg/kg/day)
Study: 32487575
Drug: Low-dose prescribing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prescribing and environment-friendly drug profiles
Study: 33176887
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus bevacizumab (10 mg/kg each i.v.)
Study: 616805373
Drug: Chiropractic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic spinal manipulative therapy
Study: 35556386
Drug: Resveratrol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (500 mg/daily for 6 weeks)
Study: 32869813
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (one of the four test breakfasts)
Study: 33506447
Drug: Steroids (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (cumulative 4-5 g) + orbital irradiation
Study: 33506447
Drug: Teprotumumab (IGF-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprotumumab (IGF-1 receptor antibody)
Study: 35238041
Drug: NSPT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSPT with 1% melatonin gel
Study: 35238041
Drug: NSPT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSPT with placebo gel
Study: 34121140
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg/day for 1 week, then 6 mg/day for 7 weeks)
Study: 32208439
Drug: Bisoprolol (beta-blocker)
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol (beta-blocker)
Study: 32208439
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor antagonist
Study: 33370571
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (2000 mg)
Study: 33067293
Drug: Happy House
Approvals — FDA: no, EMA: no, PMDA: no
Description: Happy House intervention (six weekly 90 min school-based group sessions)
Study: 32769877
Drug: Oral probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotics (3 months duration)
Study: 32769877
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise therapy (control group)
Study: 32161056
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment for breast cancer
Study: 32161056
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors treatment for breast cancer
Study: 32770730
Drug: AZD4831 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 15 mg
Study: 32770730
Drug: AZD4831 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 45 mg
Study: 32546973
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg alone once daily for seven days (Period I)
Study: 32546973
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg with linagliptin 20 mg for seven days (Period II)
Study: 32546973
Drug: Linagliptin 20
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 20 mg alone once daily for seven days (Period I)
Study: 32546973
Drug: Linagliptin 20
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 20 mg with fimasartan 120 mg for seven days (Period II)
Study: 33290915
Drug: SLIT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT plus pharmacotherapy
Study: 32925028
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication for agitation related to dementia
Study: 35344191
Drug: Once-weekly semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly semaglutide 1 mg
Study: 35344191
Drug: Once-daily canagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily canagliflozin 300 mg
Study: 33211508
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of malleable mindset and social norms
Study: 34030219
Drug: Acupressure at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure at the p6 point for 10 minutes in both hands, twice a day for two consecutive days.
Study: 32705703
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) with minimal support
Study: 34330457
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (1 g/day) for 12 weeks
Study: 32375747
Drug: Regular, low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular, low-dose (≤32 mg/day), sustained-release morphine for chronic breathlessness associated with COPD
Study: 35347300
Drug: Daily tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tadalafil plus early low-intensity shock wave therapy (LI-SWT)
Study: 35347300
Drug: Daily tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tadalafil only
Study: 32320842
Drug: Early intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensive treatment approach using one of four monoclonal antibodies as initial therapy.
Study: 32320842
Drug: Escalation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation treatment approach using any other approved medication as initial therapy with subsequent escalation to higher efficacy treatments.
Study: 35960897
Drug: Conventional Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional Radiation Therapy (CRT)
Study: 35929037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Dexmedetomidine (Dex) and Butorphanol (But)
Study: 33041028
Drug: Nucleotide supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleotide supplementation (2 g/d)
Study: 616503306
Drug: Therapy-related factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy-related factors (patient-rated pretreatment credibility and early therapeutic alliance)
Study: 35366822
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound treatment for 8 weeks
Study: 33753537
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K Antagonists (VKAs) with target INR of 2-3
Study: 33203477
Drug: Biannual community-wide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual community-wide treatment (CWT)
Study: 33203477
Drug: Annual school-based
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual school-based treatment (SBT)
Study: 33279558
Drug: Phosphate binder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate binder prescriptions and dietary recommendations to achieve 'Hi' serum phosphate target (≥6.5 mg/dl)
Study: 33279558
Drug: Phosphate binder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate binder prescriptions and dietary recommendations to achieve 'Lo' serum phosphate target (<5.5 mg/dl)
Study: 32753845
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 mg (test formulation)
Study: 32753845
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 mg (reference formulation)
Study: 32753845
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of glimepiride
Study: 32202698
Drug: Randomized spacer
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized spacer region in the translation initiation site; specific details on dosage and duration not available.
Study: 36088952
Drug: Oral amoxicillin-clavulanic
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin-clavulanic acid (75 mg/kg amoxicillin + 18.75 mg/kg clavulanic acid, given daily in three doses for 7 days)
Study: 36088952
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (according to local protocol, for 7 days)
Study: 36088952
Drug: Oral amoxicillin-clavulanic
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin-clavulanic acid
Study: 32584174
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (10 mg/site)
Study: 32584174
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl (10 mg/site)
Study: 35688444
Drug: Hyperosmolar saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar saline (593 mOsm/L)
Study: 35688444
Drug: Isotonic lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic lactated Ringer's (273 mOsm/L)
Study: 36130170
Drug: Referral resources
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral resources on evidence-based cessation treatments (control)
Study: 33185670
Drug: Evolocumab, 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab, 140 mg every 2 weeks or 420 mg monthly
Study: 33185670
Drug: Simvastatin, 40
Normalized name: Simvastatin, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 40 mg daily for 30 days followed by 80 mg daily thereafter
Study: 33185670
Drug: Ezetimibe, 10
Normalized name: Ezetimibe, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe, 10 mg daily plus simvastatin, 40 mg daily
Study: 34110701
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (CHO) - 300 ml water containing 75 g glucose
Study: 33715526
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g.kg‐1 BM)
Study: 33715526
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.3 g.kg‐1 BM)
Study: 32713104
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (STT)
Study: 32841751
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using methylene blue followed by IPL illumination
Study: 32841751
Drug: Candida antigen
Normalized name: Candida antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candida antigen immunotherapy using 0.1 ml of candida albicans antigen
Study: 32841751
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 0.1 ml saline
Study: 32845808
Drug: Bioabsorbable steroid-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable steroid-eluting sinus stents
Study: 33568346
Drug: dose-dense methotrexate-vinblastine-adriamycin-cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC), given every 14 days for four cycles
Study: 34957976
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose PTX (400 mg TID)
Study: 34957976
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose PTX (200 mg TID)
Study: 35636061
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based therapy (VRBT) once a week
Study: 33378403
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 g, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Study: 33378403
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy (esomeprazole 40 mg and amoxicillin 1 g twice daily for 14 days, adding metronidazole 500 mg and clarithromycin 500 mg twice daily in the last 7 days)
Study: 36064491
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch
Study: 32157524
Drug: Chemo/targeted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo/targeted therapy
Study: 35447085
Drug: SCB-2019 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 (two doses, 21 days apart)
Study: 35447085
Drug: SCB-2019 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 (one dose)
Study: 34024504
Drug: Dietary counselling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counselling and daily oral nutritional supplement (ONS) containing 33.8 g of protein, 2.2 g EPA, and 1.1 g DHA
Study: 32585223
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (4 intracervical injections of bupivacaine hydrochloride 0.5%)
Study: 33180175
Drug: Blonanserin (12.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin (12.8 ± 5.6 mg/day)
Study: 33180175
Drug: Olanzapine (10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10.8 ± 6.0 mg/day)
Study: 33180175
Drug: Blonanserin (D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin (D3 receptor)
Study: 33180175
Drug: Olanzapine (D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (D2 receptor)
Study: 35783867
Drug: Xinnaoning Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinnaoning Capsule (XNNC)